EnChannel Medical announced an agreement to acquire AcQMap platform assets from Acutus Medical, including intellectual property, regulatory documentation, clinical data, and a limited number of systems and catheters for R&D.
The deal follows Acutus’s strategic realignment and exit from the electrophysiology mapping and ablation business, after previously selling its left-heart access portfolio to Medtronic.
AcQMap employs voltage-to-charge-density mapping for enhanced spatial resolution. EnChannel’s integrated platform combines magnetic-impedance navigation, intracardiac echocardiography, 5D action-potential mapping, and pulsed-field ablation to advance atrial fibrillation (AF) treatment.
“This acquisition accelerates our mission to visualize and treat AF with unprecedented precision,” said Jun Feng, CEO of EnChannel Medical.
Follow MEDWIRE.AI for AFib and electrophysiology technology updates.
